Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
BTK inhibitor
Advertisement
Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
Novartis Showcases Rhapsido Data at EAACI 2026
BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...
Travere Licenses Civorebrutinib in $1.14B Kidney Disease Deal
SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...
BeOne Sets New CLL Benchmark with 78-Month BRUKINSA Data at ASCO 2026
SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...
Advertisements
InnoCare Wins China NDA Acceptance for Orelabrutinib in ITP
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
BeOne Medicines Wins FDA Approval for BEQALZI in Mantle Cell Lymphoma
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
InnoCare Advances Phase III Orelabrutinib Trial for SLE
BEIJING, April 29, 2026 InnoCare Pharma has announced that the first patient has been dosed in the registrational Phase...
Sanofi Cenrifki Wins EU CHMP Boost for Progressive MS
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
Advertisement
